GRAFT-VERSUS-HOST DISEASE (GVHD)
Clinical trials for GRAFT-VERSUS-HOST DISEASE (GVHD) explained in plain language.
Never miss a new study
Get alerted when new GRAFT-VERSUS-HOST DISEASE (GVHD) trials appear
Sign up with your email to follow new studies for GRAFT-VERSUS-HOST DISEASE (GVHD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for stem cell patients: drug combo aims to stop deadly immune attack
Disease control Recruiting nowThis study tests whether adding a new oral drug (ivarmacitinib) to standard medications can prevent acute graft-versus-host disease (GVHD) in 82 adults receiving a stem cell transplant from a female donor who has given birth. GVHD is a serious complication where donor immune cell…
Matched conditions: GRAFT-VERSUS-HOST DISEASE (GVHD)
Phase: PHASE2 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated May 26, 2026 04:03 UTC
-
Can a lower dose of transplant drug boost quality of life for older cancer patients?
Disease control Recruiting nowThis study looks at whether a lower dose of a common transplant drug can help older adults (60+) feel better after a stem cell transplant for blood cancers. The goal is to prevent graft-versus-host disease while improving quality of life. About 126 participants will receive eithe…
Matched conditions: GRAFT-VERSUS-HOST DISEASE (GVHD)
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New drug combo aims to prevent deadly transplant complication
Disease control Recruiting nowThis study tests whether a new drug combination (tacrolimus, methotrexate, and ruxolitinib) works better than the standard approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant. About 572 adults with certain blood cancers or disorders will be enrolled.…
Matched conditions: GRAFT-VERSUS-HOST DISEASE (GVHD)
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 26, 2026 03:51 UTC
-
Could a lower dose of a common drug make stem cell transplants safer?
Disease control Recruiting nowThis study is for people with blood cancers who are getting a stem cell transplant from a donor. It tests whether a lower dose of a drug called cyclophosphamide can prevent a serious side effect called graft-versus-host disease (GVHD), where donor cells attack the body. The goal …
Matched conditions: GRAFT-VERSUS-HOST DISEASE (GVHD)
Phase: PHASE2 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated May 18, 2026 12:02 UTC